▶주메뉴 바로가기
▶본문 바로가기
The US subsidiary of South Korea’s Lutronic is facing a lawsuit for allegedly misappropriating trade secrets through former employees of Cutera it hired recently, according to documents reviewed by The Korea Herald. Aesthetic laser equipment maker Cutera -- listed on Nasdaq -- claimed that ...
Prosecutors on Jan. 6 raided the headquarters of Kolon Group, as part of their investigations into alleged fraud in the listing of an affiliate involved in the development of the group‘s controversial gene therapy drug, Invossa.Prosecutors and investigators from the Seoul Central District Pros...
South Korean drugmaker Daewoong Pharmaceutical said Dec. 19 it has won approval from authorities in the United Arab Emirates and Indonesia for the sale of its botulinum toxin product. The Ministry of Health in the UAE and Indonesia’s Badan Pengawas Obat dan Makanan accepted Daewoong Pharmaceu...
Celltrion announced on Dec. 9 that it has disclosed its biosimilar Truxima’s results of phase 3 clinical trial at the 2019 annual meeting of the American Society of Hematology last week.“The clinical trials were conducted among patients in European countries including Germany, Spain and ...
South Korea’s nonlife insurance firms saw their combined net profit drop 24.6 percent in the first nine months of 2019 from a year earlier, mainly due to increased losses stemming from their long-term insurance and auto insurance businesses, data showed Dec. 2. Nonlife insurance firms operati...
SK Chemical on Nov. 27 announced that its SID 710, a patch-type medication that aims to treat people with Alzheimer’s disease has won sales approval from the US Food and Drug Administration.The patch has been sold under the name Wondron Patch, a generic version of Novartis’ Exelon Patch ...
South Korean biopharmaceutical firm Celltrion said Nov. 26 that its drug Remsima SC for the treatment of autoimmune diseases has won sales approval in Europe. The European Medicines Agency has given the green light to Celltrion’s application to sell the subcutaneous version of Remsima, a bios...
South Korean drug firm SK Biopharmaceuticals is expected to raise at least 5 trillion won ($4.25 billion) through a planned share sale, analysts said Nov. 25. The company said that XCOPRI has won approval from the US Food and Drug Administration for the treatment of partial-onset seizures in adult...
South Korean biotech firm Bridge Biotherapeutics CEO Lee Jung-kyu announced Nov. 22 that the company plans to expand further after going public in December.The company expects to be listed on the second-tier Kosdaq market. “We hope to become a global biotech company by advancing both our ...
SK Biopharmaceuticals said Nov. 22 its anti-epileptic drug has won approval from the US Food and Drug Administration. The company said the FDA granted approval of XCOPRI, or cenobamate tablets, for the treatment of partial-onset seizures in adults. This is the first time a South Korean ...
South Korea’s Samsung Bioepis said Nov. 20 that the US Food and Drug Administration has started reviewing its application for sales of SB8, a proposed biosimilar referencing Avastin.Samsung Group’s biosimilar development unit had applied for FDA’s marketing approval in September.Av...
SK Biopharm announced on Nov. 18 that its narcolepsy drug Sunosi received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP).Narcolepsy is a debilitating neurological disorder characterized by excessive sleepiness. According to SK Biop...
Celltrion Pharm, the generic arm of Celltrion, announced Nov. 14 that its sales jumped 36.6 percent in the third quarter from a year earlier to 47.43 billion won ($40.7 million).The South Korean company added that its operating profit and net profit moved into the black this quarter, respectively po...
Samsung Biologics announced Nov. 14 that it has received 27001 security certification from the Geneva-based International Organization for Standardization.The company emphasized that it is the first contract manufacturing organization to obtain ISO 27001 certification. German Ambassador to Sout...
Korean biotech firm Hugel announced Nov. 12 that its operating profit jumped 225 percent in the third quarter from a year earlier to 18.2 billion won ($15.57 million).Its sales increased by 46.4 percent to 51.1 billion won.Hugel said its overall profit improved recently due to the sales growth of it...
Samsung opens AI TV experience zone in Singapore Changi Airport
Daughter of late Samsung chairman becomes Samsung C&T president
Hana Financial teams up with Credit Agricole to expand presence in Europe
City Oil Field to export oil coverted from waste plastic to Vietnam
Baemin pays out W400b in dividends to Delivery Hero
Banks rush to cough up misselling compensation